4.5 Article

Exosome-mediated transfer of MIF confers temozolomide resistance by regulating TIMP3/PI3K/AKT axis in gliomas

Journal

MOLECULAR THERAPY-ONCOLYTICS
Volume 22, Issue -, Pages 114-128

Publisher

CELL PRESS
DOI: 10.1016/j.omto.2021.08.004

Keywords

-

Funding

  1. Natural Science Foundation of Guangdong Province [2017A030308001]
  2. NationalNatural Science Foundation of China [81874079, 82073193]
  3. Guangdong Medical Science and Technology Research Fund Project, China [A2020535]
  4. Guangdong Provincial Clinical Medical Centre for Neurosurgery [2013B020400005]

Ask authors/readers for more resources

The study showed that exosomal MIF from glioma cells contributes to TMZ resistance by promoting cell proliferation and suppressing apoptosis. Knockdown of MIF increased TMZ sensitivity by upregulating TIMP3 and inhibiting the PI3K/AKT pathway, highlighting a potential therapeutic target for TMZ treatment in gliomas.
Temozolomide (TMZ) resistance is an important cause of clinical treatment failure and poor prognosis in gliomas. Increasing evidence indicates that cancer-derived exosomes contribute to chemoresistance; however, the specific contribution of glioma-derived exosomes remains unclear. The aim of this study was to explore the role and underlying mechanisms of exosomal macrophage migration inhibitory factor (MIF) on TMZ resistance in gliomas. We first demonstrated that MIF was upregulated in the exosomes of TMZ-resistant cells, engendering the transfer of TMZ resistance to sensitive cells. Our results indicated that exosomal MIF conferred TMZ resistance to sensitive cells through the enhancement of cell proliferation and the repression of cell apoptosis upon TMZ exposure. MIF knockdown enhanced TMZ sensitivity in resistant glioma cells by upregulating Metalloproteinase Inhibitor 3 (TIMP3) and subsequently suppressing the PI3K/AKT signaling pathway. Additionally, exosomal MIF promoted tumor growth and TMZ resistance of glioma cells in vivo, while IOS-1 (MIF inhibitor) promotes glioma TMZ sensitive in vivo. Taken together, our study demonstrated that exosome-mediated transfer of MIF enhanced TMZ resistance in glioma through downregulating TIMP3 and further activating the PI3K/AKT signaling pathway, highlighting a prognostic biomarker and promising therapeutic target for TMZ treatment in gliomas.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Medicine, Research & Experimental

The role of M6A modification in the regulation of tumor-related lncRNAs

Yufei Lan, Boyang Liu, Hongbo Guo

Summary: The article summarizes the important role of N-6-methyladenosine (m(6)A) modification in the regulation and function of tumor-related long non-coding RNAs (lncRNAs), and discusses potential applications and future directions in the field.

MOLECULAR THERAPY-NUCLEIC ACIDS (2021)

Article Multidisciplinary Sciences

IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2/FPN1 signaling axis depended on NFKB2

Yufei Lan, Tao Yang, Qu Yue, Zhao Wang, Xiangyang Zhong, Xin Luo, Boming Zuo, Manqing Zhang, Tianci Zeng, Boyang Liu, Hongbo Guo

Summary: This study demonstrated, for the first time, that amplifying IRP1 signals can reverse TMZ resistance and suppress tumor growth in vivo by inhibiting NFKB2 in the noncanonical NF-kappa B signaling pathway. Additionally, we identified that NFKB2 affects the TMZ sensitivity of GBM by modulating the expression of LCN2 and FPN1. In conclusion, this study reveals the role of the IRP1/NFKB2 pathway in regulating the LCN2/FPN1 signaling axis during the progression of TMZ resistance, suggesting a potential innovative therapeutic strategy for GBM.

ISCIENCE (2023)

No Data Available